ATE450266T1 - Parapocken-viren in kombination mit klassischen zytotoxischen chemotherapeutika als biochemotherapie zur behandlung von krebs - Google Patents

Parapocken-viren in kombination mit klassischen zytotoxischen chemotherapeutika als biochemotherapie zur behandlung von krebs

Info

Publication number
ATE450266T1
ATE450266T1 AT06806214T AT06806214T ATE450266T1 AT E450266 T1 ATE450266 T1 AT E450266T1 AT 06806214 T AT06806214 T AT 06806214T AT 06806214 T AT06806214 T AT 06806214T AT E450266 T1 ATE450266 T1 AT E450266T1
Authority
AT
Austria
Prior art keywords
biochemotherapy
cancer
treatment
combination
cytotoxic chemotherapeutics
Prior art date
Application number
AT06806214T
Other languages
English (en)
Inventor
Olaf Weber
Original Assignee
Aicuris Gmbh & Co Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37654955&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE450266(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aicuris Gmbh & Co Kg filed Critical Aicuris Gmbh & Co Kg
Application granted granted Critical
Publication of ATE450266T1 publication Critical patent/ATE450266T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66Microorganisms or materials therefrom
    • A61K35/76Viruses; Subviral particles; Bacteriophages
    • A61K35/768Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/24011Poxviridae
    • C12N2710/24211Parapoxvirus, e.g. Orf virus
    • C12N2710/24232Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT06806214T 2005-11-24 2006-10-12 Parapocken-viren in kombination mit klassischen zytotoxischen chemotherapeutika als biochemotherapie zur behandlung von krebs ATE450266T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05025600 2005-11-24
PCT/EP2006/009855 WO2007059821A1 (en) 2005-11-24 2006-10-12 Parapoxviruses in combination with classical cytotoxic chemotherapeutic agents as biochemotherapy for the treatment of cancer

Publications (1)

Publication Number Publication Date
ATE450266T1 true ATE450266T1 (de) 2009-12-15

Family

ID=37654955

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06806214T ATE450266T1 (de) 2005-11-24 2006-10-12 Parapocken-viren in kombination mit klassischen zytotoxischen chemotherapeutika als biochemotherapie zur behandlung von krebs

Country Status (14)

Country Link
US (1) US7897159B2 (de)
EP (1) EP1951274B1 (de)
JP (1) JP5164849B2 (de)
CN (1) CN101312737B (de)
AR (1) AR057922A1 (de)
AT (1) ATE450266T1 (de)
CA (1) CA2630833C (de)
DE (1) DE602006010902D1 (de)
DK (1) DK1951274T3 (de)
ES (1) ES2335308T3 (de)
PL (1) PL1951274T3 (de)
PT (1) PT1951274E (de)
TW (1) TWI415617B (de)
WO (1) WO2007059821A1 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA200706804B (en) 2005-02-03 2008-10-29 Gen Hospital Corp Method for treating gefitinib resistant cancer
KR101354828B1 (ko) 2005-11-04 2014-02-18 와이어쓰 엘엘씨 mTOR 저해자, 헤르셉틴, 및/또는 HKI-272의항신생물성 조합
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
CA2725598C (en) 2008-06-17 2013-10-08 Wyeth Llc Antineoplastic combinations containing hki-272 and vinorelbine
MX2011001318A (es) 2008-08-04 2011-03-04 Wyeth Llc Combinaciones antineoplasicas de 4-anilino-3-cianoquinolinas y capecitabina.
EP2416774B1 (de) 2009-04-06 2015-11-04 Wyeth LLC Behandlungsschema mit neratinib gegen brustkrebs

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3816139A1 (de) 1987-10-17 1989-04-27 Bayer Ag Verfahren zur herstellung von paramunitaetsinducern
DE19922407A1 (de) * 1999-05-14 2000-11-16 Bayer Ag Organ-, gewebs- und zellspezifisches Immuntherapeutikum für chronische virale Infektionen, sowie entzündliche, degenerative und proliferative Erkrankungen insbesondere der Leber sowie Krebs auf der Basis von rekombinantem Parapoxvirus
CA2415397C (en) * 2000-07-11 2011-04-26 Bayer Aktiengesellschaft Use of strains of parapoxvirus ovis for producing antiviral medicaments and medicaments against cancer
AR035227A1 (es) * 2001-02-20 2004-05-05 Oncolytics Biotech Inc Uso de un agente quimioterapeutico para la manufactura de un medicamento para la sensibilizacion de celulas neoplasicas resistentes a agentes quimioterapeuticos con reovirus
NZ512341A (en) * 2001-06-13 2004-02-27 Bayer Ag Polynucleotides between 15 and 100 base pairs in length coding for parapoxvirus ovis (PPVO)/vaccinia virus recombinant (VVOV) viral genome fragments
EP2269618A1 (de) * 2002-08-12 2011-01-05 Jennerex Biotherapeutics ULC Ein onkolytisches Vaccinia-Virus zur Verwendung in Kombination mit Chemotherapie zur Behandlung von Krebs

Also Published As

Publication number Publication date
PL1951274T3 (pl) 2010-05-31
CA2630833A1 (en) 2007-05-31
TWI415617B (zh) 2013-11-21
HK1117427A1 (en) 2009-01-16
DE602006010902D1 (de) 2010-01-14
EP1951274A1 (de) 2008-08-06
CA2630833C (en) 2015-01-06
US7897159B2 (en) 2011-03-01
PT1951274E (pt) 2009-12-14
JP2009517347A (ja) 2009-04-30
DK1951274T3 (da) 2010-02-01
TW200738250A (en) 2007-10-16
ES2335308T3 (es) 2010-03-24
CN101312737A (zh) 2008-11-26
AR057922A1 (es) 2007-12-26
EP1951274B1 (de) 2009-12-02
US20090035269A1 (en) 2009-02-05
JP5164849B2 (ja) 2013-03-21
CN101312737B (zh) 2012-11-14
WO2007059821A1 (en) 2007-05-31

Similar Documents

Publication Publication Date Title
LTPA2020006I1 (lt) GDF gaudyklės, skirtos naudoti anemijos gydymui
ATE547102T1 (de) Carbolin-derivate zur behandlung von krebs
EP1765391A4 (de) Bakterielle zusammensetzungen zur behandlung von krebs
DK3567035T3 (da) N-substituerede 2,5-dioxo-azolin-forbindelser til anvendelse ved behandling af cancer
EP1888786A4 (de) Verwendung freier zirkulierender dna zur diagnose, prognose und behandlung von krebs
ATE532507T1 (de) Neramexane zur behandlung von subakuten tinnitus
ATE484192T1 (de) Verfolgbarkeitsprozess und in dem prozess verwendete sicherheitselemente
DE112012006327A5 (de) Kombinationsbehandlung (z.B. mit ABT-072 oder ABT-333 von DAAs zur Verwendung in der Behandlung von HCV)
ATE512663T1 (de) Kombination zur behandlung von erkrankungen mit zellproliferation
DE602006018057D1 (de) Substituierte chinolone und verwendungsverfahren
CL2009000200A1 (es) Compuestos derivados de 2,7-naftiridinas-1-ona, mediadores de syk; composicion farmaceutica; y uso en el tratamiento de una enfermedad inflamatoria, respiratoria, proliferativa celular o autoinmune.
IL200905A0 (en) Compounds and compositions comprising the same for use in treating hepatitis c
EA200970737A1 (ru) Оксабициклогептаны и оксабициклогептены, их получение и применение
ATE495179T1 (de) Tetrahydropyridothienpyrimidin-verbindungen und verwendung zur behandlung proliferativer erkrankungen
HRP20181727T1 (hr) Upotreba protutijela protiv čimbenika xi, namijenjena sprečavanju ili liječenju stvaranja krvnog ugruška
ATE481984T1 (de) Vakzine-peptid-kombinationen gegen katzenallergie
BRPI0819519A2 (pt) Análogos de triarilmetano e seus usos no tratamento de cânceres.
DK2235002T3 (da) 4-pyridinonforbindelser og anvendelse heraf til behandling af cancer
NO20075368L (no) Antiinflammatoriske modaliteter
EP2173337A4 (de) Phosphaplatine und ihre verwendung bei der behandlung von gegen cisplantin und carboplatin resistenten krebserkrankungen
NO20082425L (no) Formuleringer omfattende jorumycin-, reni-eramycin-, safracin- eller saframycin-relaterte forbindelser for behandling av proliferative sykdommer
EP2029172A4 (de) Antikörper gegen c35 zur behandlung von krebs
EP1863520A4 (de) Verwendung von interleukin 17e zur behandlung von krebs
ATE450266T1 (de) Parapocken-viren in kombination mit klassischen zytotoxischen chemotherapeutika als biochemotherapie zur behandlung von krebs
ATE512133T1 (de) 1h-pyrrol-2-carbonsäureamide und imidazol-5- carbonsäureamide und deren verwendung als fak-, kdr- und tie2-kinase-modulatoren zur behandlung von krebs

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1951274

Country of ref document: EP